Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Non Obstructive Urinary Retention; Overactive Bladder

Treatments: Behavioral: Filling out voiding diaries.

Study type: Interventional

Funder types: Other

Identifiers

NCT02040519

NL44879.068.13

Details and patient eligibility

About

Sacral neuromodulation (SNM) is a minimally invasive secondary treatment for overactive bladder syndrome (OAB) or for non-obstructive urinary retention (NOR), when refractory to conservative treatment. Success rates range from 70 to 80%, and good long-term results are reported. The working mechanism of SNM is not completely understood, and the only prognostic factor for good response to this treatment is a successful test stimulation period. There is no consensus on the duration of this test stimulation period. The experience in our clinic during test stimulation period is that for responders it takes up to one week to achieve maximal effect, after the system is turned 'on'. On the other hand the investigators notice that after turning the neuromodulation system 'off', it will take a few hours for symptoms to return to the baseline situation. The fact is: no information concerning the so called "time of onset" and "time of offset" (or popular called: wash-in / wash-out) of sacral neuromodulation is available in current literature.

Enrollment: 45 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients should have been diagnosed with overactive bladder syndrome and should be put on the waiting list for scheduling treatment with sacral neuromodulation.

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

• patients receiving neurological or psychiatric medication without being diagnosed with a neurological or psychiatric disease
• patients who have been treated by means of bladder wall botulin toxin injections in the previous year
• patients with evident subsequent complaints of bladder pain syndrome or other pelvic pain

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

45 participants in 1 patient group

Evaluation by voiding diaries

Experimental group

Treatment:

Behavioral: Filling out voiding diaries.